BACKGROUND AND PURPOSE: In patients with large-core infarcts, the risk and clinical implications of posttreatment intracranial hemorrhage (ICH) remain poorly understood. We aimed to characterize the frequency, patterns, predictors, and prognostic relevance of posttreatment ICH in patients with large-core infarcts treated in the Efficacy and Safety of Thrombectomy in Stroke With Extended Lesion and Extended Time Window (TENSION) trial. MATERIALS AND METHODS: We performed a post hoc analysis of 253 patients with anterior circulation stroke and an ASPECTS score of 3–5 randomized to either mechanical thrombectomy (MT) plus best medical treatment (BMT) or BMT alone. Hemorrhages were categorized both clinically (symptomatic versus asymptomatic) and radiologically using the Heidelberg Bleeding Classification. Predictors of parenchymal hematoma (PH) and symptomatic intracranial hemorrhage (sICH) were identified using logistic regression. The association between bleeding severity and 90-day outcome was evaluated using multivariable models. RESULTS: Any ICH occurred in 45.1% of patients, more frequently after MT compared with BMT (54.4% versus 35.9%; P = .004), mostly asymptomatic. Among patients with any ICH, hemorrhagic infarction was associated with the highest rate of favorable outcome (34.0%) and was equally distributed across treatment arms. PHs were more common after MT (23.2% versus 9.4%; P = .004). Predictors of PH included MT itself (adjusted OR [aOR] 2.11; 95% CI, 1.11–3.99), higher NIHSS (aOR 1.13; 95% CI, 1.04–1.23), and larger core volume (aOR 1.003; 95% CI, 1.000–1.005). No independent predictors of sICH were identified. In adjusted models, bleeding severity was not associated with poor outcome, whereas age, NIHSS, and core volume were. Importantly, MT remained independently associated with better functional outcomes, even when adjusting for hemorrhagic events. However, the benefit of MT appeared attenuated in patients who developed PH, as shown by a significant treatment interaction. CONCLUSIONS: ICH is common in large-core stroke, particularly after MT, but is often asymptomatic and not independently linked to poor outcome. PH may reduce the benefit of MT, but overall, MT remains associated with improved functional outcomes. Distinguishing hemorrhage types is crucial in assessing posttreatment risk in this vulnerable population. aOR : adjusted odds ratio BMT : best medical treatment HBC : Heidelberg Bleeding Classification HI : hemorrhagic infarction ICH : intracranial hemorrhage LVO : large vessel occlusion MT : mechanical thrombectomy PH : parenchymal hematoma sICH : symptomatic intracranial hemorrhage TENSION : Efficacy and Safety of Thrombectomy in Stroke With Extended Lesion and Extended Time Window

Beyond lifelong physical conditions, cancer survivorship can bring long-term mental health concerns, such as anxiety, depression and isolation. In an effort to support cancer survivors, researchers from Drexel University are exploring music therapy as a way to better understand what they're going through and help them manage these posttreatment challenges.

SB5052: A bill to address the health of cancer survivors and unmet needs that survivors face through the entire continuum of care from diagnosis through active treatment and posttreatment, in order to improve survivorship, treatment, transition to recovery and beyond, quality of life and palliative care, and long-term health outcomes, including by developing a minimum standard of care for cancer survivorship, irrespective of the type of cancer, a survivor's background, or forthcoming survivorship needs, and for other purposes.

This cohort study assesses the outcomes of rituximab-treated patients with immunodeficiency associated with anti–interferon-γ autoantibodies for as long as 4 years of posttreatment follow-up.

Bepirovirsen reduced posttreatment markers of hepatitis B infection at 72 weeks, with 20% of recipients achieving functional cure vs none given placebo.

Jane Iredale After Glow Post Treatment Kit is a post-treatment, four‑piece post‑treatment set designed to hydrate, protect and soothe sensitised skin. The kit is designed to support recovery while hel...

HB8839: To address the health of cancer survivors and unmet needs that survivors face through the entire continuum of care from diagnosis through active treatment and posttreatment, in order to improve survivorship, treatment, transition to recovery and beyond, quality of life and palliative care, and long-term health outcomes, including by developing a minimum standard of care for cancer survivorship, irrespective of the type of cancer, a survivor's background, or forthcoming survivorship needs, and for other purposes.

Gilead Sciences (Nasdaq:GILD) received FDA accelerated approval for Hepcludex (bulevirtide-gmod) 8.5 mg, the first and only approved U.S. treatment for chronic hepatitis delta virus (HDV) in adults, with or without compensated cirrhosis.Approval is based on HDV RNA reductions and ALT normalization in Phase 3 MYR301; improvement in clinical outcomes is not yet established. Hepcludex carries a boxed warning for severe posttreatment exacerbation of hepatitis D and B and requires close hepatic monitoring after discontinuation.

Jane Iredale After Glow Post Treatment Kit is a post-treatment, four‑piece post‑treatment set designed to hydrate, protect and soothe sensitised skin. The kit is designed to support recovery while hel...

The costs of posttreatment care are forcing cancer survivors to make tough choices. GOP proposals to bring down health insurance costs won’t help people who need constant care and monitoring, health p...

Read the full paper: Expansion of stemlike HIV-specific CD8+ T cells and limited viral epitope diversity characterize durable posttreatment control of HIV